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Super-enhancers are large clusters of transcriptional
enhancers that drive expression of genes that define
cell identity. Improved understanding of the roles
that super-enhancers play in biology would be
afforded by knowing the constellation of factors
that constitute these domains and by identifying
super-enhancers across the spectrum of human
cell types. We describe here the population of tran-
scription factors, cofactors, chromatin regulators,
and transcription apparatus occupying super-en-
hancers in embryonic stem cells and evidence that
super-enhancers are highly transcribed. We produce
a catalog of super-enhancers in a broad range of hu-
man cell types and find that super-enhancers asso-
ciate with genes that control and define the biology
of these cells. Interestingly, disease-associated vari-
ation is especially enriched in the super-enhancers of
disease-relevant cell types. Furthermore, we find that
cancer cells generate super-enhancers at onco-
genes and other genes important in tumor pathogen-
esis. Thus, super-enhancers play key roles in human
cell identity in health and in disease.INTRODUCTION
Transcription factors bind DNA regulatory elements called en-
hancers, which play key roles in the control of cell-type-specific
gene expression programs (Bulger and Groudine, 2011; Calo
and Wysocka, 2013; Carey, 1998; Lelli et al., 2012; Levine and
Tjian, 2003; Maston et al., 2006; Ong and Corces, 2011; Panne,
2008; Spitz and Furlong, 2012; Xie and Ren, 2013). A typical
mammalian cell contains thousands of active enhancers, and it
has been estimated that there may be 1 million enhancers
active in all human cells (Bernstein et al., 2012; Heintzman
et al., 2009; Thurman et al., 2012). It is important to further under-
stand enhancers and their components because they control
specific gene expression programs, and much disease-associ-
ated sequence variation occurs in these regulatory elements934 Cell 155, 934–947, November 7, 2013 ª2013 Elsevier Inc.(Grossman et al., 2013; Hindorff et al., 2009; Lee and Young,
2013; Maurano et al., 2012).
The set of enhancers that control any one cell’s gene expres-
sion program is probably best defined in murine embryonic stem
cells (ESCs). Co-occupancy of murine ESC genomic sites by the
master transcription factors Oct4, Sox2, and Nanog is highly
predictive of enhancer activity (Chen et al., 2008), and 8,794 en-
hancers have been identified in ESCs by using ChIP-seq data
sets for Oct4, Sox2, and Nanog (Whyte et al., 2013). A subset
of these enhancers forms 231 unusual enhancer domains at
most genes that control the pluripotent state; these super-
enhancers consist of clusters of enhancers that are densely
occupied by five key ESC transcription factors and the Mediator
coactivator (Whyte et al., 2013). There are many additional tran-
scription factors, cofactors, and chromatin regulators that
contribute to the control of ESCs (Ng and Surani, 2011; Orkin
and Hochedlinger, 2011; Young, 2011), and it would be instruc-
tive to know how these occupy enhancers and super-enhancers
in ESCs. Similarly, it would be useful to know if super-enhancers
are transcribed, as enhancer RNAs (eRNAs) have been pro-
posed to contribute to enhancer activity (Lai et al., 2013; Lam
et al., 2013; Li et al., 2013; Ling et al., 2004; Mousavi et al.,
2013; Ørom et al., 2010).
Super-enhancers are associated with key genes that control
cell state in cells where they have been identified thus far, so
identification of these domains in additional cell types could pro-
vide a valuable resource for further study of cellular control. We
have generated a catalog of super-enhancers in 86 human cell
and tissue types. These super-enhancers are associated with
genes encoding cell-type-specific transcription factors and
thus identify candidate master transcription factors for many
cell types that should prove useful for further understanding
transcriptional control of cell state and for reprogramming
studies. Using this catalog, we find that DNA sequence variation
associated with specific diseases is especially enriched in the
super-enhancers of disease-relevant cells, suggesting that
hypotheses regarding the role of specific cell types and genes
in many diseases might be guided by knowledge of super-
enhancers. Furthermore, tumor cells acquire super-enhancers
at key oncogenes and at genes that function in the acquisition
of hallmark capabilities in cancer, suggesting that these
domains provide biomarkers for tumor-specific pathologies
that may be valuable for diagnosis and therapeutic intervention.
We discuss the implications of these observations for future
study of disease.
RESULTS
Transcription Factors in ESCs
Super-enhancers are clusters of enhancers—formed by binding
of high levels of master transcription factors and Mediator coac-
tivator—that drive high-level expression of genes encoding key
regulators of cell identity (Figure 1A) (Whyte et al., 2013). Five
ESC transcription factors were previously shown to occupy
super-enhancers (Oct4, Sox2, Nanog, Klf4, and Esrrb) (Whyte
et al., 2013), but there are many additional transcription factors
that contribute to the control of ESCs (Ng and Surani, 2011; Orkin
and Hochedlinger, 2011; Young, 2011). We compiled ChIP-seq
data for 15 additional transcription factors in ESCs, for which
high-quality ChIP-seq data were available, and investigated
whether they occupy enhancers defined by Oct4, Sox2, and
Nanog (OSN) co-occupancy (Whyte et al., 2013) (Table S1 avail-
able online). The analysis showed that six additional transcription
factors (Nr5a2, Prdm14, Tcfcp2l1, Smad3, Stat3, and Tcf3)
occupy both typical enhancers and super-enhancers and that
all of these are enriched in super-enhancers (Figures 1B–1E).
Each of these factors has previously been shown to play impor-
tant roles in ESC biology (Ng and Surani, 2011; Orkin and
Hochedlinger, 2011; Young, 2011). In contrast, nine other tran-
scription factors (c-Myc, CTCF, Zfx, Tbx3, YY1, Tfe3, Kap1/
Zfp57, Smad1, and Ronin) were not similarly enriched in en-
hancers (Table S1) and instead occupied other regions of the
genome such as promoter-proximal sites or sites that border
topological domains (Figure S1A). It is particularly interesting
that Smad3, Stat3, and Tcf3 are enriched in super-enhancer
domains because these are transcription factor targets of the
TGF-b-, LIF-, and Wnt-signaling pathways, respectively. Previ-
ous studies have shown that these transcription factors are
recruited to enhancers formed by master transcription factors
(Chen et al., 2008; Mullen et al., 2011), and evidence for enrich-
ment of these factors at super-enhancers shows how these
signaling pathways can converge on key genes that control
ESC identity.
To assess whether the 11 transcription factors that are en-
riched at super-enhancers contribute to super-enhancer forma-
tion by binding to known DNA sequence motifs, we analyzed the
frequency of these bindingmotifs at super-enhancer regions. For
all nine transcription factors for which binding motifs are avail-
able, we found that the cognate motif showed significant enrich-
ment at super-enhancer constituents relative to background
expectation, and super-enhancers were enriched for these
motifs compared to typical enhancers (Figures 1F, S1B, and
S1C). These results suggest that the nine transcription factors
contribute to super-enhancers by binding directly to their known
DNA sequence motifs.
Previous studies have described a model of core transcrip-
tional regulatory circuitry that includes Oct4, Sox2, and Nanog
(Boyer et al., 2005). The evidence that these and additional
ESC transcription factors form super-enhancers that drive
genes that are essential for control of cell identity suggests a
revised model of transcriptional regulatory circuitry for ESCs(Figure 1G). This model contains an interconnected autoregula-
tory loop like that originally proposed for Oct4, Sox2, and
Nanog (Boyer et al., 2005) but consists of the additional ESC
transcription factors that meet three criteria: (1) their genes are
driven by super-enhancers, (2) they co-occupy their own
super-enhancers as well as those of the other master genes,
and (3) they play important roles in regulation of ESC state and
iPSC reprogramming.
RNA Polymerase II, Cofactors, and Chromatin
Regulators
Super-enhancers are occupied by unusually high levels of the
Mediator coactivator (Whyte et al., 2013). Previous studies
have described the activities of RNA polymerase II and various
cofactors, chromatin regulators, and RNA at specific enhancers
(Calo and Wysocka, 2013; Kagey et al., 2010; Lai et al., 2013;
Lam et al., 2013; Li et al., 2013; Ling et al., 2004; Mousavi
et al., 2013; Natoli and Andrau, 2012; Ong and Corces, 2011;
Ørom et al., 2010), so we used published and newly generated
ChIP-seq and RNA-seq data to investigate how these compo-
nents are associated with enhancers and super-enhancers
across the ESC genome. The results indicate that RNA polymer-
ase II, Mediator, cohesin, Nipbl, p300, CBP, Chd7, Brd4, and
components of the esBAF (Brg1) and Lsd1-NuRD complexes
are all enriched in super-enhancers relative to typical enhancers
(Figures 2A–2E and Table S1). RNA polymerase II can transcribe
enhancers, producing noncoding RNAs that in some cases
contribute to enhancer activity (Kim et al., 2010; Lam et al.,
2013; Li et al., 2013; Natoli and Andrau, 2012; Sigova et al.,
2013); we found that RNA polymerase II and RNA were highly
enriched at super-enhancers relative to typical enhancers
(Figure 2C).
It was notable that a broad spectrum of cofactors and chro-
matin regulators that are responsible for gene activation,
enhancer looping, histone modification, and nucleosome re-
modeling are especially enriched in ESC super-enhancers. The
Mediator coactivator binds Nipbl, which loads cohesin, thus
facilitating looping of enhancers to the promoters of their target
genes (Kagey et al., 2010). The coactivator p300 is a histone
acetyltransferase, which is generally found at enhancer regions
(Heintzman et al., 2007; Visel et al., 2009). CBP is a transcrip-
tional coactivator that interacts with p300 and promotes synergy
between enhancer components (Merika et al., 1998). Chd7 is a
chromatin remodeler that also interacts with p300 and is often
found at enhancers (Schnetz et al., 2010). Brd4, a member of
the bromodomain protein family, binds to Mediator and acety-
lated histones and is involved in regulation of transcriptional
elongation by RNA polymerase II (Jang et al., 2005; Jiang
et al., 1998). Brg1 is a subunit of the mammalian esBAF (SWI/
SNF) complex, an ATP-dependent chromatin remodeler, which
contributes to maintenance of pluripotency and self-renewal in
ESCs (Ho et al., 2009a; Ho et al., 2009b). Lsd1, Hdac1, Hdac2,
Mi-2b, and Mbd3 are subunits of the Lsd1-NuRD complex,
which possesses histone deacetylase-, demethylase-, and
nucleosome-remodeling activities and contributes to enhancer
decommissioning during differentiation (Denslow and Wade,
2007; Foster et al., 2010; Kaji et al., 2006, 2007; Reynolds
et al., 2012a, 2012b; Shi et al., 2004; Whyte et al., 2012).Cell 155, 934–947, November 7, 2013 ª2013 Elsevier Inc. 935
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Figure 1. Transcription Factors at Super-Enhancers
(A) Distribution of Med1 ChIP-seq signal at enhancers reveals two classes of enhancers in ESCs. Enhancer regions are plotted in an increasing order based on
their input-normalized Med1 ChIP-seq signal. Super-enhancers are defined as the population of enhancers above the inflection point of the curve. Example
super-enhancers are highlighted along with their respective ranks and their associated genes.
(B) ChIP-seq binding profiles for the indicated transcription factors at the POLE4 andmiR-290–295 loci in ESCs. Red dots indicate the median enrichment of all
bound regions in the respective ChIP-seq data sets and are positioned at maximum 20% of the axis height. rpm/bp, reads per million per base pair.
(legend continued on next page)
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Super-enhancers are occupied by an unusually large portion
of the enhancer-associated RNA polymerase II and its asso-
ciated cofactors and chromatin regulators. As measured by
ChIP-seq reads, between 12% and 36% of RNA polymerase
II and the cofactors associated with all 8,794 enhancers were
found within the 231 super-enhancers (Figure 2C). The evi-
dence that a large fraction of these enhancer cofactors are
associated with super-enhancers helps to explain why these
large domains produce relatively high levels of RNA (Figure 2C)
and drive high-level expression of their associated genes when
compared to typical enhancers (Whyte et al., 2013). The pres-
ence of high levels of RNA at super-enhancers is especially
interesting in light of recent studies suggesting that enhancer
RNA contributes to gene activation (Lai et al., 2013; Lam
et al., 2013; Li et al., 2013; Ling et al., 2004; Mousavi et al.,
2013; Ørom et al., 2010) and evidence that the MYOD1
super-enhancer is transcribed into eRNAs that contribute
to the transcriptional activation of MYOD1 in muscle cells
(Mousavi et al., 2013).
ESC differentiation causes preferential loss of expression of
super-enhancer-associated genes, which may be a conse-
quence of the unusual vulnerability of super-enhancers to pertur-
bation of their components (Dowen et al, 2013; Love´n et al.,
2013; Whyte et al., 2013) (Figures S2A–S2C). We speculate
that this dual feature of super-enhancers—their ability to drive
high-level expression of key regulators of cell identity and their
vulnerability to perturbation of their components—may facilitate
cell state transitions during development.
Super-Enhancers in Many Cell Types
Because super-enhancers drive expression of genes that control
and define cell identity, it would be useful to identify these ele-
ments and their associated genes in all human cells. However,
the master transcription factors that might form super-en-
hancers are not known for most cell types, and genome-wide
binding data are limited for those that are known. We therefore
explored the ability of various surrogate marks of enhancers (his-
tone H3K27ac, H3K4me1, DNase hypersensitivity, and p300) to
identify super-enhancers in ESCs (Creyghton et al., 2010;
Heintzman et al., 2007; Neph et al., 2012; Rada-Iglesias et al.,
2011; Shen et al., 2012; Visel et al., 2009). Of the marks available
for a broad range of human samples, the histone H3K27acmodi-
fication was superior to the others in that it identified a large frac-(C) Metagene representations of the mean ChIP-seq signal for the indicated t
Metagenes are centered on the enhancer region, and the length of the enhancer r
for super-enhancers). Additional 3 kb surrounding each enhancer region is also
(D) Fold difference values of ChIP-seq signal between typical enhancers and sup
mean ChIP-seq signal (total reads) at typical enhancers and super-enhancers no
ChIP-seq density at constituent enhancers (rpm/bp) of typical enhancers and supe
% indicates the percentage of all reads mapped to enhancer regions that fall in
(E) Metagene representations of the mean ChIP-seq density for the indicated trans
super-enhancers. Each metagene is centered on enhancer constituents. Additio
(F) Table depicting transcription factor binding motifs enriched at constituent en
(G) Revised model of the core transcriptional regulatory circuitry of ESCs. The mo
factors that meet three criteria: (1) their genes are driven by super-enhancers,
transcription factor genes in the circuit, and (3) they play essential roles in regulat
adapted from Whyte et al. (2013).
See also Figure S1 and Table S1.tion of OSN-Mediator super-enhancers while minimizing excess
sites (Figure S3A).
We used H3K27ac ChIP-seq data to create a catalog of super-
enhancers for 86 human cell and tissue samples (Figure 3 and
Table S2). A substantial portion of these super-enhancers and
their associated genes are cell type specific (Figures 3A
and S3B). In contrast, typical enhancer-associated genes are
less cell type specific (Figure S3C). Characterization of super-
enhancer-associated genes byGene Ontology analysis revealed
that they are linked to biological processes that largely define the
identities of the respective cell and tissue types (Figure 3B).
Some of the super-enhancer domains overlap previously
described locus control regions (LCRs), transcription initiation
platforms (TIPs), andDNAmethylation valleys (DMV) (Figure S3D)
(Bonifer, 2000; Forrester et al., 1990; Grosveld et al., 1987; Koch
et al., 2011; Tuan et al., 1985; Xie and Ren, 2013).
To gain further understanding of the transcriptional regulatory
circuitry of cells and to facilitate efforts to reprogram cells for
regenerativemedicine, it would be valuable to identify themaster
transcription factors that control all cell states (Cherry and Daley,
2012; Graf and Enver, 2009; Lee and Young, 2013; Zhou et al.,
2008). Super-enhancers were previously identified in five murine
cell types (ESC, myotubes, pro-B cells, Th cells, and macro-
phages), and the genes encoding known master transcription
factors in these cells were found to have associated super-en-
hancers (Whyte et al., 2013). We reasoned that candidate master
transcription factors could be identified in most cells by identi-
fying genes associated with super-enhancers that encode tran-
scription factors and carried out this analysis in all of the cells in
this study. For those cells where master transcription factors
have already been identified, this exercise captured the vast ma-
jority of these factors (Figure 3C). A catalog of candidate master
transcription factors for other cell types can be found in Table S3.
Prior studies of key transcriptional regulators suggest that these
candidates should be useful for deducing the transcriptional reg-
ulatory circuitry ofmany different human cells and for reprogram-
ming studies.
Disease-Associated DNA Sequence Variation in Super-
Enhancers
Several recent studies suggest that much of disease-associated
DNA sequence variation occurs in transcriptional regulatory re-
gions defined by DNase hypersensitivity (Maurano et al., 2012;ranscription factors across typical enhancers and super-enhancer domains.
eflects the difference in median lengths (703 bp for typical enhancers, 8,667 bp
shown.
er-enhancers for the indicated transcription factors. Total signal indicates the
rmalized to the mean value at typical enhancers. Density indicates the mean
r-enhancers normalized to themean value at typical enhancers. Enhancer read
the constituents of typical enhancer or super-enhancer regions.
cription factors across the constituent enhancers within typical enhancers and
nal 2.5 kb surrounding the constituent enhancer regions is also shown.
hancers within super-enhancer regions and associated p values.
del contains an interconnected autoregulatory loop consisting of transcription
(2) they co-occupy their own super-enhancers as well as those of the other
ion of ESC state and iPSC reprogramming. The layout of the circuit model was
Cell 155, 934–947, November 7, 2013 ª2013 Elsevier Inc. 937
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Figure 2. RNA Polymerase II, Cofactors, and Chromatin Regulators at Super-Enhancers
(A) ChIP-seq binding profiles for RNA polymerase II (RNAPII) and the indicated transcriptional cofactors and chromatin regulators at the POLE4 andmiR-290-295
loci in ESCs. OSN denotes the merged ChIP-seq binding profiles of the transcription factors Oct4, Sox2, and Nanog and serves as a reference. Red dots indicate
(legend continued on next page)
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Vernot et al., 2012). We investigated the extent to which disease-
associated DNA sequence variation occurs in enhancers and su-
per-enhancers defined by histone H3K27ac. We compiled a list
of 5,303 single-nucleotide polymorphisms (SNP) linked to
diverse phenotypic traits and diseases in 1,675 genome-wide
association studies (GWAS) and investigated their distribution
within enhancers and super-enhancers identified in the 86 hu-
man cell and tissue samples (Figure 4A and Table S4). We found
that the majority of trait-associated SNPs occur in noncoding re-
gions and that 64% of these occur within enhancer regions
defined by H3K27ac (Figure 4A). Thus, 64% of trait-associated
noncoding SNPs occur in the 33% of the genome covered
by all enhancer regions defined by H3K27ac (permutation test,
p < 104). The trait-associated SNPs were more enriched in
super-enhancers than in typical enhancers (c2 test, p < 1012)
(Figure S4A), and for certain diseases, the enrichment in super-
enhancers was particularly striking (Figure S4B). These results
confirm that much of disease-associated DNA sequence varia-
tion occurs in transcriptional regulatory regions of the genome,
indicate that most of this variation occurs in enhancers, and
reveal that variation disproportionately impacts super-enhancer
domains.
If disease-associated SNPs occur disproportionately in super-
enhancer domains, we would expect that SNPs associated with
specific diseases would tend to occur in the super-enhancers of
disease-relevant cells and not in those of disease-irrelevant
cells. Indeed, for a broad spectrum of diseases, we found that
disease-associated SNPs tend to occur in the super-enhancers
of disease-relevant cells (Figure 4B and Table S4). This relation-
ship was more pronounced for super-enhancers than for typical
enhancers (Figure S4C). Because super-enhancers drive the
expression of genes that control and define cell identity, these
results suggest that altered expression of cell identity genes
may often contribute to these diseases.
Examples of Disease-Associated SNPs in Super-
Enhancers
We focused further study on several diseases in which SNPs
occur in super-enhancers of disease-relevant cell types in order
to gain further insights into the relationship between these SNPs,
specific super-enhancers, and their associated genes. The dis-
eases that we selected for further study included Alzheimer’sthemedian enrichment of all bound regions in the respective ChIP-seq data sets a
per base pair.
(B) Metagene representations of the mean ChIP-seq signal for RNAPII and the
enhancers and super-enhancer domains. Metagenes are centered on the enha
lengths (703 bp for typical enhancers, 8,667 bp for super-enhancers). Additional
(C) Fold difference values of ChIP-seq signal between typical enhancers and
chromatin regulators and RNA-seq. Total signal indicates the mean ChIP-seq si
mean value at typical enhancers. Density indicates the mean ChIP-seq density
normalized to themean value at typical enhancers. Enhancer read% indicates the
of typical enhancer or super-enhancer regions. Reads mapped to exons were re
(D) Metagene representations of the mean ChIP-seq density for RNAPII and the
stituent enhancers within typical enhancers and super-enhancers. Each metag
constituent enhancer regions is also shown.
(E) Model showing RNAPII, transcriptional cofactors, and chromatin regulators tha
diverse enhancer-related functions, such as enhancer looping, gene activation, n
See also Figure S2 and Table S1.disease, type 1 diabetes, and systemic lupus erythematosus
(Figure 5).
Alzheimer’s disease is a common form of dementia character-
ized by progressive neurodegeneration and loss of cognitive
functions of the brain, and much of the genetic variation impli-
cated in Alzheimer’s disease is associated with amyloid precur-
sor protein, transmembrane proteins, and apolipoprotein E4
(Bertram and Tanzi, 2008; Tanzi, 2012). The SNP catalog con-
tains 27 SNPs linked to Alzheimer’s disease, and five of these
occur in the super-enhancers of brain tissue (Figure 5A). Thus,
19% (5/27) of all of the Alzheimer’s disease SNPs occur in
the 1.4% of the genome encompassed by brain tissue super-
enhancers (permutation test, p < 102). Two SNPs occur in the
super-enhancer associated with the gene BIN1 (Figure 5A),
whose expression has recently been shown to be associated
with Alzheimer’s disease risk (Chapuis et al., 2013). Additional
variation in the BIN1 super-enhancer, involving a small insertion,
was shown to be associated with Alzheimer’s disease (Chapuis
et al., 2013).
Type 1 diabetes is caused by T-cell-mediated autoimmune
destruction of pancreatic b cells, and much of the genetic varia-
tion implicated in type 1 diabetes is associated with major histo-
compatibility antigens, interleukin-2 signaling, T cell receptor
signaling, and interferon signaling (Bluestone et al., 2010; Noble
and Erlich, 2012). The SNP catalog contains 76 SNPs linked to
type 1 diabetes, and 67 of these occur in noncoding sequences.
The noncoding SNPs were particularly enriched in the super-
enhancers of primary Th cells, with 13 occurring in the super-
enhancer regions of genes with prominent roles in Th cell biology
(Figure 5B). It was striking that 19% (13/67) of all of the type 1 dia-
betes SNPs in noncoding regions occur in the 1.3% of the
genome encompassed by Th cell super-enhancers (permutation
test, p < 104).
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease characterized by the loss of tolerance for
self-antigens and production of excess amounts of serum auto-
antibodies. Most genetic variation associated with SLE involves
major histocompatibility antigens and lymphocyte-signaling
pathways (Costa-Reis and Sullivan, 2013; Deng and Tsao,
2010). The SNP catalog contains 72 SNPs linked to SLE, and
67 of these occur in noncoding regions. Among the cell types
examined here, the noncoding SNPs occur most frequently innd are positioned at maximum 20%of the axis height. rpm/bp, reads per million
indicated transcriptional cofactors and chromatin regulators across typical
ncer region, and the length of the enhancer reflects the difference in median
3 kb surrounding each enhancer region is also shown.
super-enhancers for RNAPII and the indicated transcriptional cofactors and
gnal (total reads) at typical enhancers and super-enhancers normalized to the
at constituent enhancers (rpm/bp) of typical enhancers and super-enhancers
percentage of all readsmapped to enhancer regions that fall in the constituents
moved for the RNA-seq analysis.
indicated transcriptional cofactors and chromatin regulators across the con-
ene is centered on enhancer constituents. Additional 2.5 kb surrounding the
t are found in ESC super-enhancers. The indicated proteins are responsible for
ucleosome remodeling, and histone modification.
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Figure 3. Super-Enhancers and Candidate Master Transcription Factors in Many Cell Types
(A) Heatmap showing the classification of super-enhancer domains across 26 human cell and tissue types. Color scale reflects the density of H3K27ac signal at
the super-enhancer regions.
(B) Gene Ontology terms for super-enhancer-associated genes in 14 human cell and tissue types with corresponding p values.
(C) Candidate master transcription factors identified in six cell types. All of these transcription factors were previously demonstrated to play key roles in the
biology of the respective cell type or facilitate reprogramming to the respective cell type.
See also Figure S3 and Tables S2 and S3.B cell super-enhancers, with 22 SNPs occurring in the super-
enhancer regions of 16 genes that play key roles in B cell biology
(Figure 5C). Thus, 33% (22/67) of the SLE SNPs in noncoding re-
gions occur in the 1.5% of the genome encompassed by B cell
super-enhancers (permutation test, p < 104).
Similar enrichment of disease-associated variation in super-
enhancers was observed for many additional diseases, in-
cluding rheumatoid arthritis, multiple sclerosis, systemic
scleroderma, primary biliary cirrhosis, Crohn’s disease, Graves940 Cell 155, 934–947, November 7, 2013 ª2013 Elsevier Inc.disease, vitiligo, and atrial fibrillation (Table S4). This suggests
that hypotheses regarding the role of specific cell types and
genes in many diseases might be guided by knowledge of
super-enhancers.
Super-Enhancers in Cancer
Super-enhancers associate with key oncogenes in several can-
cer cells (Love´n et al., 2013). To gain further insights into the rela-
tionship between super-enhancers and cancer cell states, we
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Figure 4. Disease-Associated DNA Sequence Variation in Super-
Enhancers
(A) Catalog of single-nucleotide polymorphisms (SNP) linked to phenotypic
traits and diseases in genome-wide association studies (GWAS). (Left) Pie
chart showing percentage of SNPs associated with the highlighted classes of
traits and diseases. (Middle) Distribution of trait-associated SNPs in codingused H3K27ac ChIP-seq data to identify super-enhancers in 18
human cancer cells and identified their associated genes (Table
S2). The data revealed that a remarkable spectrum of known
oncogene drivers have associated super-enhancers in this set
of cancer cells (Figure 6A and Table S2). These results suggest
that super-enhancers may be useful for identifying key onco-
genes in specific cancers.
Further analysis of super-enhancers in tumor cells and related
healthy cells suggests that cancer cells acquire super-enhancers
at oncogene drivers during the process of tumor pathogenesis
(Figure 6B). For example, for multiple cancer cells, large super-
enhancers were found in the gene desert surrounding the
c-MYC gene in the cancer cells, but not in their healthy counter-
parts (Figure 6B). Furthermore, the super-enhancers formed in
the MYC locus were tumor type specific (Figures 6B and S5).
These results are consistent with the model that cancer cells ac-
quire cancer-specific super-enhancers at key oncogenes that
are not present in their healthy counterparts.
DNA translocation, transcription factor overexpression, and
focal amplification occur frequently in cancer, and these mech-
anisms can account for the ability of cancer cells to acquire
super-enhancers (Figure 6C). In multiple myeloma, for example,
tumor cells often have a translocation that places the 30 IgH
super-enhancer adjacent to the MYC gene (Figure 6C). Overex-
pression of the TAL1 transcription factor in acute lymphoblastic
leukemia (T-ALL) is associated with super-enhancer formation at
another site in the MYC locus (Figure 6C). Focal amplification in
lung cancer involves a large super-enhancer that spans theMYC
gene and its normal regulatory elements (Figure 6C); tandem re-
peats of DNA segments can lead to the formation of clusters of
enhancers.
Hanahan and Weinberg (2011) have proposed that cancer
cells acquire a number of hallmark biological capabilities during
the multistep process of tumor pathogenesis (Hanahan and
Weinberg, 2011).We used these hallmarks as an organizing prin-
ciple to investigate whether genes that acquire super-enhancers
are associated with these biological capabilities in tumor cells.
We identified super-enhancers that were acquired by cancer
cells (not present in a healthy counterpart) and determined
how their associated genes fit into the hallmarks. The results of
such analysis with a colorectal cancer line revealed that more
than one-third of the super-enhancer genes have functions
that are associated with a cancer hallmark (Figures 6D, 6E,
and Table S5). A similar analysis of two additional cancer lines
confirmed that a large fraction of genes that acquire super-
enhancers have hallmark functions (Figure 6E and Table S5).and noncoding regions of the genome. (Right) Location of all noncoding trait-
associated SNPs relative to all enhancers identified in 86 human cell and tissue
samples. x axis reflects binned distances of each SNP to the nearest
enhancer. SNPs located within enhancers are assigned to the 0 bin.
(B) Radar plots showing the density of trait-associated noncoding SNPs linked
to the highlighted traits and diseases in the super-enhancer domains identified
in 12 human cell and tissue types. The center of the plot is 0, and a colored dot
on the respective axis indicates the SNP density (SNP/10 MB sequence) in the
super-enhancer domains of each cell and tissue type. Lines connecting the
density values to the origin of the plot are added to improve visualization.
See also Figure S4 and Tables S2 and S4.
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Figure 5. Examples of Disease-Associated SNPs
in Super-Enhancers
(A) (Upper-left) Radar plots showing the density of
noncoding SNPs linked to Alzheimer’s disease (AD) in
the super-enhancer domains and typical enhancers
identified in 12 human cell and tissue types. The center
of the plot is 0, and a colored dot on the respective axis
indicates the SNP density (SNP/10 MB sequence) in the
super-enhancer domains or typical enhancers of each
cell and tissue type. Lines connecting the density values
to the origin of the plot are added to improve visualiza-
tion. (Upper-right) Distribution of noncoding SNPs linked
to AD in the typical enhancers and super-enhancers of
brain tissue. (Lower-left) List of genes associated with
AD SNP-containing super-enhancers in brain tissue.
(Lower-right) ChIP-seq binding profile for H3K27ac at
the BIN1 locus in brain tissue. The positions of AD SNPs
are highlighted as red bars, and the super-enhancers
are highlighted as black bars above the binding profile.
Indel rs59335482 (a three base pair insertion) is also
highlighted. rpm/bp, reads per million per base pair.
(B) (Upper-left) Radar plots showing the density of
noncoding SNPs linked to type 1 diabetes (T1D) in the
super-enhancer domains and typical enhancers identi-
fied in 12 human cell and tissue types. The center of the
plot is 0, and a colored dot on the respective axis in-
dicates the SNP density (SNP/10 MB sequence) in the
super-enhancer domains or typical enhancers of each
cell and tissue type. Lines connecting the density values
to the origin of the plot are added to improve visualiza-
tion. (Upper-right) Distribution of noncoding SNPs linked
to T1D in the typical enhancers and super-enhancers of
Th cells. (Lower-left) List of genes associated with T1D
SNP-containing super-enhancers in Th cells. (Lower-
right) ChIP-seq binding profile for H3K27ac at the IL2RA
locus in Th cells. The positions of T1D SNPs are high-
lighted as red bars, and the super-enhancers are high-
lighted as black bars above the binding profile.
(C) (Upper-left) Radar plots showing the density of
noncoding SNPs linked to systemic lupus erythemato-
sus (SLE) in the super-enhancer domains and typical
enhancers identified in 12 human cell and tissue types.
The center of the plot is 0, and a colored dot on the
respective axis indicates the SNP density (SNP/10 MB
sequence) in the super-enhancer domains or typical
enhancers of each cell and tissue type. Lines connecting
the density values to the origin of the plot are added to
improve visualization. (Upper-right) Distribution of non-
coding SNPs linked to SLE in the typical enhancers and
super-enhancers of B cells. (Lower-left) List of genes
associated with SLE SNP-containing super-enhancers
in B cells. (Lower-right) ChIP-seq binding profile for
H3K27ac at the HLA-DRB1 and HLA-DQA1 loci in B
cells. The positions of SLE SNPs are highlighted as red
bars, and the super-enhancers are highlighted as black
bars above the binding profile.
See also Tables S2 and S4.
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Figure 6. Super-Enhancers in Cancer
(A) Selected genes associated with super-enhancers in the indicated cancers. Blue box indicates the gene being associated with a super-enhancer in the
respective cancer. CML stands for chronic myelogenous leukemia.
(legend continued on next page)
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We conclude that cancer cells acquire cancer-specific super-
enhancers at genes whose functions are associated with these
hallmarks of cancer.
DISCUSSION
Super-enhancers were previously identified in a small number of
cells, where they were shown to consist of large clusters of tran-
scriptional enhancers formed by binding of master transcription
factors and to be associated with genes that control and define
cell identity (Love´n et al., 2013; Whyte et al., 2013). We have
extended our understanding of super-enhancers by identifying
the population of transcription factors, cofactors, chromatin reg-
ulators, and core transcription apparatus that occupy these
domains in embryonic stem cells and by demonstrating that
super-enhancers are highly transcribed. We have created a cat-
alog of super-enhancers for 86 different human cell and tissue
types and have shown that these are associated with genes en-
coding cell-type-specific transcription factors and other compo-
nents that play important roles in cell-type-specific biology.Most
importantly, we find that sequence variation associated with a
broad spectrum of diseases is especially enriched in the
super-enhancers of disease-relevant cell types and that cancer
cells generally acquire super-enhancers at oncogenes and other
genes that play important roles in cancer pathogenesis.
The enhancers and transcription factors that control embry-
onic stem cell state are probably better understood than those
for any other cell type, making ESCs an excellent model for iden-
tifying components of super-enhancers (Ng and Surani, 2011;
Orkin and Hochedlinger, 2011; Young, 2011). Several important
insights were gained by studying how >35 transcription factors,
cofactors, chromatin regulators, and components of the core
transcription apparatus occupy enhancers and super-enhancers
in ESCs. All of the enhancer-binding transcription factors are
enriched at super-enhancers, with some so highly enriched
that they distinguish super-enhancers from typical enhancers.
The transcription factor targets of the TGF-b-, LIF-, and Wnt-
signaling pathways are enriched in super-enhancers, suggesting
how these signaling pathways converge on key genes that con-(B) Cancer cells acquire super-enhancers. ChIP-seq binding profiles for H3K27a
leukemia, colorectal cancer, and healthy counterparts. In colorectal cancer, sever
MYC gene in colorectal cancer (Ahmadiyeh et al., 2010; Pomerantz et al., 2009).
(C) Chromosomal translocation, overexpression of transcription factors, and focal
are ChIP-seq binding profiles for H3K27ac and indicated transcription factors at th
event places theMYC gene proximal to an inserted IgH super-enhancer in multiple
leukemia. (Bottom) Large H3K27ac domains are observed at the site of focal a
the genomic positions of focal amplification in six different samples, two of whic
2013).
(D) Tumor-specific super-enhancers associate with hallmark cancer genes in c
Hanahan and Weinberg, 2011. Genes associated with super-enhancers in colo
categories based on their functions and their previous implication in tumorigene
highlighted at each cancer hallmark. (Bottom) Distribution of H3K27ac signal acros
the identification of 387 super-enhancers. Prominent genes associated with supe
their respective super-enhancer ranks and cancer hallmarks that they were assig
(E) Super-enhancers acquired by cancer cells associate with hallmark genes. Ea
genes that are associated with acquired super-enhancers and are included in that
above genomic expectation (hypergeometric test, p < 0.05).
See also Figure S5 and Tables S2 and S5.
944 Cell 155, 934–947, November 7, 2013 ª2013 Elsevier Inc.trol ESC identity. Super-enhancers are occupied by a large
portion of the enhancer-associated RNA polymerase II and its
associated cofactors and chromatin regulators, which can
explain how they contribute to high-level transcription of
associated genes. Furthermore, the levels of RNA detected at
super-enhancers vastly exceed those at typical enhancers,
and recent evidence suggests that these eRNAs may con-
tribute to gene activation (Lai et al., 2013; Lam et al., 2013; Li
et al., 2013; Ling et al., 2004; Mousavi et al., 2013; Ørom et al.,
2010).
We have generated a catalog of super-enhancers and their
associated genes in a broad spectrum of human cell and tissue
types. The super-enhancers tend to be cell type specific, and the
genes associated with these elements tend to be cell type spe-
cific in their expression and linked to biological processes that
largely define the identities of the respective cell and tissue
types. Genes that encode candidate master transcription factors
and noncoding RNAs such as miRNAs are among those associ-
ated with super-enhancers. Thus, the super-enhancer catalog
should provide a valuable resource for further study of transcrip-
tional control of cell identity and for reprogramming (Cherry and
Daley, 2012; Graf and Enver, 2009; Lee and Young, 2013; Zhou
et al., 2008).
Several recent studies suggest that much of disease-associ-
ated DNA sequence variation occurs in transcriptional regulatory
regions defined by DNase hypersensitivity (Maurano et al., 2012;
Vernot et al., 2012). We found that disease-associated SNPs
occur in super-enhancers of disease-relevant cells and that
this occurs more frequently for super-enhancers than for typical
enhancers. Because super-enhancers drive the expression of
genes that control and define cell identity, these results suggest
that altered expression of cell identity genes may often
contribute to these diseases. These observations also suggest
that hypotheses regarding the role of specific cell types and
genes in many diseases might be guided in the future by knowl-
edge of super-enhancers.
Cancer cells acquire super-enhancers at oncogene drivers
during the process of tumor pathogenesis. Cancer cells appear
to acquire super-enhancers through a variety of mechanisms,c are shown at the gene desert surrounding MYC in pancreatic cancer, T cell
al regions in the 1MBwindow upstream ofMYCwere shown to interact with the
rpm/bp, reads per million per base pair.
amplificationmay contribute to super-enhancer formation in cancer. Displayed
e gene desert surroundingMYC in the indicated cancers. (Top) A translocation
myeloma. (Middle) Tal1 binding is observed at a distal super-enhancer in T cell
mplification in lung cancer. The red bars below the binding profiles indicate
h (SM09-019T and SM09-11T1) are primary patient samples (Iwakawa et al.,
olorectal cancer. (Top) Diagram of the ten hallmarks of cancer adapted from
rectal cancer, but not in healthy colon samples, were assigned to hallmark
sis. Prominent genes that associate with tumor-specific super-enhancers are
s enhancers identified in colorectal cancer. Uneven distribution of signal allows
r-enhancers in colorectal cancer, but not in healthy colon, are highlighted with
ned to.
ch cancer hallmark was assigned a Gene Ontology term, and the number of
GO term is displayed for each cancer. Asterisk denotes statistical significance
including chromosomal translocation of super-enhancers
normally associated with other genes, focal amplification, or
overexpression of an oncogenic transcription factor. The
super-enhancers acquired by cancer cells are associated with
a remarkably broad spectrum of oncogenes that have been
described thus far in cancer (Bishop, 1987; Fearon and Vogel-
stein, 1990; Forbes et al., 2010; Futreal et al., 2004; Garraway
and Lander, 2013; Hanahan and Weinberg, 2011; Vogelstein
et al., 2013). They are also associated with genes that function
in the acquisition of hallmark capabilities in cancer (Hanahan
and Weinberg, 2011). These results suggest that super-
enhancers can provide biomarkers for cancer-specific pathol-
ogies that may be valuable for further understanding cancer
biology, diagnosis, and therapy.EXPERIMENTAL PROCEDURES
Data Analysis
ChIP-seq data sets were aligned using Bowtie (version 0.12.9) to build version
mm9 of the mouse genome or version hg19 of the human genome. The GEO
accession IDs for all analyzed data sets are listed in Table S6.
Normalized read density of a ChIP-seq data set in any region was calculated
as described (Whyte et al., 2013). ChIP-seq reads aligning to the region were
extended by 200 bp, and the density of reads per base pair (bp) was calcu-
lated. The density of reads in each region was normalized to the total number
of million mapped reads producing read density in units of reads per million
mapped reads per base pair (rpm/bp).
We used the MACS version 1.4.1 (model-based analysis of ChIP-seq)
(Zhang et al., 2008) peak-finding algorithm to identify regions of ChIP-seq
enrichment over background. A p value threshold of enrichment of 1 3 10–9
was used for all data sets.
Enhancers were defined as regions of ChIP-seq enrichment for transcription
factors in murine ESCs and H3K27ac in human cells. To accurately capture
dense clusters of enhancers, we allowed enhancer regions within 12.5 kb of
one another to be stitched together.
The methods for identifying super-enhancers and the assignment of
enhancers to genes are fully described in the Supplemental Information.ACCESSION NUMBERS
The CBP, Mbd3, and Ronin ChIP-seq data in mESCs; the H3K27ac ChIP-seq
data in RPMI-8402; and the RNA-seq data inmESCs have been deposited with
the Gene Expression Omnibus under the accession ID GSE51522.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, six tables, and two data files and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2013.09.053.
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